@danacucc's GLP-1 goodbye video raises questions

What did @danacucc actually say?

Honestly? It's not entirely clear. The transcript reads more like a song lyric or a partially transcribed audio clip than a direct medical or lifestyle claim. The phrases "goodbye," "losing me for life," and what appears to be fragmented text suggest this is either a lip-sync, a dubbed audio track, or a caption-generated mess. There's no explicit GLP-1 claim in the transcript itself.

The video is categorized under GLP-1 content and tagged with body positivity and confidence hashtags, which strongly implies this is a before/after or "farewell to my old body" style post, common in the semaglutide and tirzepatide creator space. But we can only fact-check what was actually said, and what was actually said is ambiguous at best.

Does the science back this up?

If this is a body transformation post tied to GLP-1 use, the underlying premise, that these medications produce meaningful weight loss, is well-supported. The science here is solid, even if the video's messaging is vague.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that semaglutide 2.4mg weekly produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. Tirzepatide outcomes were even more pronounced: the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% body weight reduction at the highest dose. These are not trivial numbers. For people who have struggled with weight for years, that kind of result genuinely changes lives.

What the science does not support is the idea that weight loss equals permanent transformation without ongoing treatment. The STEP 4 trial (Rubino et al., 2021, JAMA) showed significant weight regain after stopping semaglutide, which is something body-positive farewell posts rarely mention.

What did they get wrong (or right)?

We can't pin specific errors on @danacucc because the transcript doesn't contain specific medical claims. That's actually worth noting. A lot of GLP-1 content on TikTok makes bold, often unsupported claims about dosing, compounded equivalency, or miracle-level outcomes. This video, at least in its transcript, doesn't do that.

What it does do is participate in a broader cultural narrative: that GLP-1 weight loss is a clean "goodbye" to a former self. That framing can be emotionally compelling but clinically misleading. Weight loss from these medications often plateaus, requires indefinite use to maintain, and comes with side effects ranging from nausea to more serious gastrointestinal events (Davies et al., 2021, Diabetes Care). The triumphant exit narrative skips all of that.

If the video is body-positive in intent, that's genuinely fine. But pairing that with GLP-1 content creates an implicit endorsement of the drug as a confidence fix, which oversimplifies both the treatment and the person using it.

What should you actually know?

GLP-1 receptor agonists are FDA-approved medications for chronic weight management and type 2 diabetes. They work by mimicking a gut hormone that regulates appetite and insulin secretion. They are not a shortcut, and they are not a personality transplant.

Several things the "farewell body" genre of content consistently leaves out: these drugs require a prescription and medical supervision; side effects are common and occasionally serious; weight regain after discontinuation is well-documented; and compounded versions of semaglutide or tirzepatide are not equivalent to FDA-approved brand-name products like Wegovy or Zepbound, regardless of what some sellers claim.

If you're considering a GLP-1 medication, the right starting point is a licensed clinician, not a TikTok trend. Platforms like FormBlends connect patients with actual providers who can assess whether these medications are appropriate for their specific situation, including medical history, current medications, and realistic expectations.